Xencor, Inc. and CSL Ltd. have entered into a technology license agreement that provides CSL with access to Xencor’s Xtend technology to optimize CSL’s monoclonal antibodies. CSL will be granted an exclusive license to use Xtend half-life extension technology in its program against an undisclosed target. Xencor will receive an upfront payment and is eligible to receive preclinical, clinical, regulatory and sales milestone payments, as well as royalties on product sales. Financial ter...